Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure

Ramsey M. Wehbe, Sadiya S. Khan, Sanjiv J. Shah, Faraz S. Ahmad*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations

Abstract

Identifying patients with heart failure at high risk for poor outcomes is important for patient care, resource allocation, and process improvement. Although numerous risk models exist to predict mortality, hospitalization, and patient-reported health status, they are infrequently used for several reasons, including modest performance, lack of evidence to support routine clinical use, and barriers to implementation. Artificial intelligence has the potential to enhance the performance of risk prediction models, but has its own limitations and remains unproved.

Original languageEnglish (US)
Pages (from-to)387-407
Number of pages21
JournalHeart Failure Clinics
Volume16
Issue number4
DOIs
StatePublished - Oct 2020

Funding

S.J. Shah is supported by grants from the National Institutes of Health ( R01 HL140731 , R01 HL120728 , R01 HL107577 , and R01 HL149423 ); the American Heart Association ( #16SFRN28780016 , #15CVGPSD27260148 ); Actelion , AstraZeneca , Corvia , and Novartis ; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics. F.S. Ahmad is supported in part by a grant from the Agency for Healthcare Research and Quality ( K12 HS026385 ) and has received consulting fees from Amgen. S.S. Khan is supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (KL2TR001424). The other authors have nothing to disclose. S.J. Shah is supported by grants from the National Institutes of Health (R01 HL140731, R01 HL120728, R01 HL107577, and R01 HL149423); the American Heart Association (#16SFRN28780016, #15CVGPSD27260148); Actelion, AstraZeneca, Corvia, and Novartis; and has received consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Cardiora, Eisai, Ionis, Ironwood, Merck, Novartis, Pfizer, Sanofi, and United Therapeutics. F.S. Ahmad is supported in part by a grant from the Agency for Healthcare Research and Quality (K12 HS026385) and has received consulting fees from Amgen. S.S. Khan is supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (KL2TR001424). The other authors have nothing to disclose.

Keywords

  • Artificial intelligence
  • Deep learning
  • Heart failure
  • Machine learning
  • Prognosis
  • Risk factors
  • Risk models
  • Risk scores

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Predicting High-Risk Patients and High-Risk Outcomes in Heart Failure'. Together they form a unique fingerprint.

Cite this